NCT04217967 is a Phase 4 clinical trial of Ixazomib in Multiple Myeloma, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT04217967?

NCT04217967 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04217967?

Interventions in NCT04217967: Ixazomib, Lenalidomide.

What condition does NCT04217967 study?

NCT04217967 studies Multiple Myeloma.

Is NCT04217967 still recruiting?

NCT04217967 is currently completed. Last updated 1 August 2024.

Last reviewed 2024-08-01 · How we verify

NCT04217967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Completed Phase 4 Last updated 1 August 2024

What this trial tests

Phase 4 trial testing Ixazomib in Multiple Myeloma in 211 participants. Completed in 30 June 2024.

Timeline

24 September 2019

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	211
Start date	24 September 2019
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	1 location across China

Drugs / interventions tested

Ixazomib (IXAZOMIB) — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440
Targeting proteostasis for cancer therapy: current advances, challenges, and future perspectives.
Zhang C, Li J, Tang Q, Li L, et al · · 2025 · cited 4× · PMID 41121138 · DOI 10.1186/s12943-025-02472-x
Publication Only
· 2025
P873: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
Zhuang Z, Tian Y, Shi L, Yu H, et al · · 2023
P959: MAINTENANCE THERAPY FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANTATION BY IXAZOMIB AND/OR LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTICENTERED REAL WORLD STUDY IN CHINA
Lu M, Liu A, Chen W, Wu Y, et al · · 2023
Abstract Book for the 27th Congress of the European Hematology Association
· 2022
P978: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
Zhuang Z, Tian Y, Yu H, Shi L, et al · · 2022
P-143: Breakthrough – a designated pharmacist in the hemato-oncology department improves both quality and sequence of drug treatment and reduces ADR in Multiple Myeloma patients during Covid-19 pandemic
Alabbasi A, Cohen S, Green M, Brammli S, et al · · 2021

Verify or expand the search:

Other trials of Ixazomib

Trials testing the same drug.

NCT05722405 — Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma · Phase 4 · recruiting
NCT05183139 — A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide an · Phase 4 · withdrawn
NCT04998786 — A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myel · Phase 2 · active not recruiting
NCT04837131 — A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients · Phase 2 · terminated
NCT03888534 — Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphob · Phase 1 · withdrawn

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04217967 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 1 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04217967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing